Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients
A simple and sensitive method for the simultaneous detection of imatinib mesylate and its active metabolite, N-desmethylimatinib, in human serum samples was developed. Separation was successfully achieved using an Agilent® ZORBAX Eclipse plus Cis reversed phase column (50 x 2.1 mm, i.d.; 1.8 pm) u...
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/60900/1/TAN%20KA%20LIONG%20-%20e.pdf |
| _version_ | 1817928299103387648 |
|---|---|
| author | Liong, Tan Ka |
| author_facet | Liong, Tan Ka |
| author_sort | Liong, Tan Ka |
| collection | USM |
| description | A simple and sensitive method for the simultaneous detection of imatinib mesylate
and its active metabolite, N-desmethylimatinib, in human serum samples was developed. Separation was successfully achieved using an Agilent® ZORBAX
Eclipse plus Cis reversed phase column (50 x 2.1 mm, i.d.; 1.8 pm) under isocratic
mobile phase conditions consisting of acetonitrile: 0.02 M potassium dihydrogen
phosphate with 0.2% triethylamine added at pH 3 (25:75, v/v) and ultra-violet
detection at 235 nm. Extraction of the target compounds was completed by a protein
precipitation method using 100% cold acetonitrile. Good linearities (r2 > 0.99) for Ndesmethyhmafaob
and imatinib mesylate were achieved for the concentration ranges
of 50-360 ng/mL and 50-1800 ng/mL, respectively. The detection limits were 20
ng/mL and 10 ng/mL for N-desmethylimatinib and imatinib mesylate, respectively.
The intra- and inter-day precisions were less than 1% while the percentage recoveries
were more than 95%. The method was successfully applied to calculate the
pharmacokinetic parameters of chronic myeloid leukemia patients receiving imatinib.
For imatinib, mean Vd was 113.32 ± 43.52 L, CL was 5.012 ± 0.028 L and AUC was
62953.33 ± 9791.38 ng.h.L’1. For N-desmethylimatirab, mean Vd was 415.27 ±
228.72 L, CL was 4.84 ± 3.85 L and AUC was 5585.15 ± 2950.42 ng.h.L’1. The
method is suitable to be routinely applied for determination of ZV-ctesTnetAyZimatinib
and imatinib mesylate in serum. |
| first_indexed | 2024-12-09T02:32:07Z |
| format | Thesis |
| id | usm.eprints-60900 |
| institution | Universiti Sains Malaysia |
| language | English |
| last_indexed | 2024-12-09T02:32:07Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | usm.eprints-609002024-11-17T07:05:29Z http://eprints.usm.my/60900/ Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients Liong, Tan Ka R Medicine RC254-282 Neoplasms. Tumors. Oncology (including Cancer) RC648-665 Diseases of the endocrine glands. Clinical endocrinology A simple and sensitive method for the simultaneous detection of imatinib mesylate and its active metabolite, N-desmethylimatinib, in human serum samples was developed. Separation was successfully achieved using an Agilent® ZORBAX Eclipse plus Cis reversed phase column (50 x 2.1 mm, i.d.; 1.8 pm) under isocratic mobile phase conditions consisting of acetonitrile: 0.02 M potassium dihydrogen phosphate with 0.2% triethylamine added at pH 3 (25:75, v/v) and ultra-violet detection at 235 nm. Extraction of the target compounds was completed by a protein precipitation method using 100% cold acetonitrile. Good linearities (r2 > 0.99) for Ndesmethyhmafaob and imatinib mesylate were achieved for the concentration ranges of 50-360 ng/mL and 50-1800 ng/mL, respectively. The detection limits were 20 ng/mL and 10 ng/mL for N-desmethylimatinib and imatinib mesylate, respectively. The intra- and inter-day precisions were less than 1% while the percentage recoveries were more than 95%. The method was successfully applied to calculate the pharmacokinetic parameters of chronic myeloid leukemia patients receiving imatinib. For imatinib, mean Vd was 113.32 ± 43.52 L, CL was 5.012 ± 0.028 L and AUC was 62953.33 ± 9791.38 ng.h.L’1. For N-desmethylimatirab, mean Vd was 415.27 ± 228.72 L, CL was 4.84 ± 3.85 L and AUC was 5585.15 ± 2950.42 ng.h.L’1. The method is suitable to be routinely applied for determination of ZV-ctesTnetAyZimatinib and imatinib mesylate in serum. 2013-03 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/60900/1/TAN%20KA%20LIONG%20-%20e.pdf Liong, Tan Ka (2013) Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients. Masters thesis, Universiti Sains Malaysia. |
| spellingShingle | R Medicine RC254-282 Neoplasms. Tumors. Oncology (including Cancer) RC648-665 Diseases of the endocrine glands. Clinical endocrinology Liong, Tan Ka Ultra-high performance liquid chromatography (uhplc) method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients |
| title | Ultra-high performance liquid chromatography
(uhplc) method development and validation for the
determination of serum imatinib and its active
metabolite concentration among chronic myeloid
leukemia patients |
| title_full | Ultra-high performance liquid chromatography
(uhplc) method development and validation for the
determination of serum imatinib and its active
metabolite concentration among chronic myeloid
leukemia patients |
| title_fullStr | Ultra-high performance liquid chromatography
(uhplc) method development and validation for the
determination of serum imatinib and its active
metabolite concentration among chronic myeloid
leukemia patients |
| title_full_unstemmed | Ultra-high performance liquid chromatography
(uhplc) method development and validation for the
determination of serum imatinib and its active
metabolite concentration among chronic myeloid
leukemia patients |
| title_short | Ultra-high performance liquid chromatography
(uhplc) method development and validation for the
determination of serum imatinib and its active
metabolite concentration among chronic myeloid
leukemia patients |
| title_sort | ultra high performance liquid chromatography uhplc method development and validation for the determination of serum imatinib and its active metabolite concentration among chronic myeloid leukemia patients |
| topic | R Medicine RC254-282 Neoplasms. Tumors. Oncology (including Cancer) RC648-665 Diseases of the endocrine glands. Clinical endocrinology |
| url | http://eprints.usm.my/60900/1/TAN%20KA%20LIONG%20-%20e.pdf |
| work_keys_str_mv | AT liongtanka ultrahighperformanceliquidchromatographyuhplcmethoddevelopmentandvalidationforthedeterminationofserumimatinibanditsactivemetaboliteconcentrationamongchronicmyeloidleukemiapatients |